Results 31 to 40 of about 50,558 (217)

Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report

Frontiers in Pharmacology, 2023
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies.
Xuechun Mu, Yujiao Duan, Qiuhua Xu, Sa Wang, Guiju Gao, Ning Han, Hongxin Zhao   +6 more
doaj   +1 more source

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel [PDF]

, 2018
Dasabuvir is mainly metabolized by cytochrome P450 (CYP) 2C8 and is predominantly used in a regimen containing ritonavir. Ritonavir and clopidogrel are inhibitors of CYP3A4 and CYP2C8, respectively. In a randomized, crossover study in 12 healthy subjects,
Neuvonen, Pertti J., Outi Lapatto‐Reiniluoto, Neuvonen, Mikko, Matti K. Itkonen, Tornio, Aleksi, Itkonen, Matti K., Mikko Niemi, Mikko Neuvonen, Niemi, Mikko, Aleksi Tornio, Janne T. Backman, Pertti J. Neuvonen, Backman, Janne T., Lapatto-Reiniluoto, Outi   +13 more
core   +1 more source

Ritonavir May Inhibit Exoribonuclease Activity of Nsp14 from the SARS-CoV-2 Virus and Potentiate the Activity of Chain Terminating Drugs [PDF]

, 2020
SARS-CoV-2 is the causative agent for the ongoing COVID19 pandemic, and this virus belongs to the Coronaviridae family. The nsp14 protein of SARS-CoV-2 houses a 3’ to 5’ exoribonuclease activity responsible for removing mismatches that arise during ...
deepak t, nair, naveen, narayanan
core   +1 more source

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. [PDF]

, 2010
Contains fulltext : 87324.pdf (Publisher’s version ) (Open Access)HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis.
Burger, DM, Faraj, D., Burger, David M., Luin, M. van, Kuks, P.F.M., Ven, A. van der, van Luin, M, Faraj, Diari, Visser, M. de, Wit, Ferdinand W., van Schaik, Ron, Burger, D.M., Visser, M., Schaik, R.H.N. van, Kroon, Frank, Kuks, Paul Fm, Ende, Marchina, Kuks, PFM, van Schaik, Ron Hn, Ende, M.E. van der, Richter, C, Gelinck, Luc, Wit, FW, Gelinck, L., van Luin, Matthijs, Visser, Mirjam, Visser, Martje, Faraj, D, Kroon, F., van de Ven, A, Ven, A.J.A.M. van der, Kroon, F, Richter, C., Wit, F.W., Schaik, R.H. van, Richter, Clemens, van der Ven, Andre, van der Ende, Marchina E.   +37 more
core   +1 more source

Study of the Pharmaceutical Grade Polymers effect on the Dissolution of Practically Insoluble Antiretroviral Substances

Разработка и регистрация лекарственных средств, 2022
Introduction. Many of new active pharmaceutical ingredients (APIs) have low solubility that can affect bioavailability negatively and therefore therapeutically efficacy as well.
S. A. Zolotov, N. B. Demina, E. S. Ponomarev, I. A. Dain, A. S. Zolotova   +4 more
doaj   +1 more source

Accelerating Discovery of Organic Molecular Crystals via Materials Informatics and Autonomous Experiments

Advanced Intelligent Discovery, EarlyView.
Materials informatics and autonomous experimentation are transforming the discovery of organic molecular crystals. This review presents an integrated molecule–crystal–function–optimization workflow combining machine learning, crystal structure prediction, and Bayesian optimization with robotic platforms.
Takuya Taniguchi, Kazuki Ishizaki, Ryo Fukasawa   +2 more
wiley   +1 more source

Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy [PDF]

, 2003
Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Gough, K., Walmsley, S., Raboud, J., Tseng, A., Phillips, E., Rubin, G., Thompson, C., Abdurrahman, Z., Loutfy, M., Kovacs, C., Rachlis, A.   +10 more
core  

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

, 2008
Background: Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful.
Pulido Ortega, Federico, Rubio García, Rafael, Norton, Michael   +2 more
core   +1 more source

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? [PDF]

, 2011
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can ...
Braun, Patrick, Ehret Robert, Naeth, Gudrun, Frank Wiesmann, Tappe André, Tappe, André, Rolf Kaiser, Martin Stürmer, Hauke Walter, Jan Vachta, Walter, Hauke, André Tappe, Ehret, Robert, Stürmer Martin, Thomas Berg, Kaiser Rolf, Robert Ehret, Berg Thomas, Naeth Gudrun, Knechten Heribert, Gudrun Naeth, Patrick Braun, Knechten, Heribert, Stürmer, Martin, Wiesmann, Frank, Vachta, Jan, Heribert Knechten, Kaiser, Rolf, Berg, Thomas, Walter Hauke, Martin Däumer, Braun Patrick, Däumer Martin, Wiesmann Frank, Vachta Jan, Däumer, Martin   +35 more
core   +1 more source

A case report of drug–drug interaction between voriconazole and simnotrelvir/ritonavir

Frontiers in Antibiotics
Co-administration of simnotrelvir/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole.
Tingting Chen, Qingquan Zhang
doaj   +1 more source